In anticipation of the launch of the inaugural New Frontiers in Research Fund (NFRF) Transformation Stream competition in the coming weeks, and in consideration that these applications are complex, ALL applications, including those led by other institutions, require Faculty endorsement. **If you intend to apply to the Transformation Stream competition, either as Principal Investigator or as a Co-Investigator, or on an application being led by another institution, inform the HRS research office of your intention by copy on a completed Expression of Interest (EOI) form sent to Grace Kim, Assistant Director-Development, ROADS, at kimps@mcmaster.ca by October 15th.**

Please note, the program description, requirements and processes outlined below are subject to change following additional information from the agency.

**OVERVIEW:** The Transformation Stream is designed to support large-scale, Canadian-led interdisciplinary research projects that address a major challenge with the potential to realize real and lasting change (high reward). The challenge may be fundamental, leading to a scientific breakthrough, or applied, with a social, economic, environmental or health impact. Projects are expected to be world-leading, drawing on global research expertise, where relevant.

The Transformation stream grants will support projects that:
- tackle a well-defined problem or challenge;
- propose a novel world-leading approach that is different from the current state-of-the-art approaches to the issue;
- are interdisciplinary, bringing different perspectives to the defined problem; and
- have the potential to be transformative, defined as the potential to create a significant and real change or impact—a noticeable leap or tangible breakthrough versus an incremental advance.

**VALUE:** It is anticipated that the inaugural competition will fund a total of 6-8 projects. Transformation stream grants will provide up to $4 million per year, including indirect costs, for up to six years. Successful applications will be awarded up to a 3-year grant initially. A mid-term review is mandatory to ensure projects are on track and meeting objectives. Following a successful mid-term review, a second (and final) grant for the remaining duration (maximum of three years) will be awarded.

**INFORMATION SESSION:** The Research Office for Administration, Development & Support (ROADS) has organized an information session on the Transformation Stream competition. In addition to ROADS staff, an NFRF review panel member will be in attendance to answer any questions you may have. Details are as follows:

**Friday, October 4th**
MDCL Room 2232
1:00pm to 2:30 pm

To register: [https://nfrf.eventbrite.ca](https://nfrf.eventbrite.ca)

**APPLICATION PROCESS:**
Since Transformation Stream applications are complex, all applications, including those led by McMaster and those where we partner on proposals led by other institutions, require Faculty endorsement.
MITACS – leveraging partner funds to source funds for trainees

While the MITACS program has been around a long time, it has undergone some significant changes to both programs and structure, and it is an underutilized source for funding trainee experiences. Consider leverage your existing partnered funding to apply for added funds for trainee management, travel and collaborative programs. Ongoing applications, simplified submission procedures, and high success rates!

- Eligible partners include companies (anywhere in the world!) and not-for-profits (Canada)
- Get funding for projects big or small (4 months to 4 years or longer)
- Funding includes both stipends and research expenses


Mitacs Industrial Postdoc Accelerate Program

The Mitacs Accelerate industrial postdoc provides 1, 2 or 3 years of funding – valued at $55,000 per year - for a postdoctoral fellow in any discipline. This special initiative offers better leveraging than standard Mitacs Accelerate internships.

<table>
<thead>
<tr>
<th></th>
<th>Per year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partner contribution</td>
<td>$25,000</td>
</tr>
<tr>
<td>Total research funding</td>
<td>$55,000</td>
</tr>
</tbody>
</table>

| Minimum postdoc stipend/salary | $50,000 |
| Maximum funds for research costs | $5,000 |

Postdoctoral fellows partner with a company or not-for-profit organization and build a longer-term research collaboration.

Companies and organizations gain a competitive advantage by adding a highly-skilled member to their teams while postdoctoral fellows apply their expertise to real-world problems and build business-ready skills.

Apply from October 16th to December 6th, 2019.

Michael G. DeGroote Health Innovation, Commercialization and Entrepreneurship (MGD Health ICE)

FALL 2019 ENGAGEMENT OPPORTUNITIES

To learn more about MGD Health Innovation, Commercialization & Entrepreneurship offerings, please email Sarrah Lal (sarrah@mcmaster.ca) and visit our website (healthinnovation.mcmaster.ca). You can stay up-to-date by joining our weekly mailing list.

#1 - HEALTH VENTURE PROGRAM

What if your research project turned into the next big health venture? If you are a researcher, clinician or student interested in exploring health innovation opportunities, or simply want to build up your business acumen by learning about commercialization, this program is for you! The Health Venture Program is currently accepting applications to both the Development Stream and Accelerated Stream offerings.

a) Development Stream (6 Modules at 5-7 PM) | Deadline passed |
Clinicians, Researchers and Staff | $250
Students, Trainees and Medical Residents | $150
Early bird discount of 20% applies until five days prior to the session

This program provides an opportunity to take evaluate the commercialization potential of your research project or innovative idea. Build your innovation project portfolio alongside a community of like-minded peers, faculty members, mentors and industry experts. The HVP Development Stream takes place in the Burke Science Building (BSB) on the main McMaster University campus.

SESSION DATES

Module 2 – October 7 – Intellectual Property and Venture Creation vs Licensing
Module 4 – November 11 – Team Creation, Value Articulation and Pitching
Module 5 – November 25 – Go-to-Market Strategies and Raising Capital
Module 6 – December 9 – Final Pitches & Next Step Discussions

b) Accelerated Stream (Full Day Session | 8 AM – 4 PM) | Register here

Clinicians, researchers and staff | $250
Students, Trainees and Medical Residents | $150
Early bird discount of 20% applies until five days prior to the session. For start-up companies interested in attending this offering, please email sarrah@mcmaster.ca directly.

This program introduces you to core concepts of health innovation, commercialization and entrepreneurship, as they apply to a category of health innovation. Build a network of like-minded peers, faculty members, mentors and industry experts. The HVP Accelerated Stream takes place at the Centre for Continuing Education (1 James St. N).

UPCOMING SESSIONS

October 17 - Integrated Care Programs
November 21 - Innovations in a Global Context
December 5 - Medical Devices and Therapeutics

All sessions include topics such as industry overviews, human-centered design, venture creation vs. licensing deals, innovation procurement, prototyping methods, go-to-market strategy, raising capital, and team building. Please contact Sarrah Lal (sarrah@mcmaster.ca) directly for session-specific topics.

#2 - SPRINT COMPETITION – BUILDING A VIRTUAL TRAVEL CLINIC | REGISTER HERE by September 30

How might Hamilton Health Sciences (HHS) leverage telemedicine to create a virtual travel clinic? Come out to learn more about emerging technologies, build up your entrepreneurship acumen and propose a model of care that can meet the travel care needs of local and non-local patients. Recommendations made to the HHS team at the end of the Sprint will help inform their emerging virtualization strategy.

October 3  5:30 – 8:30 PM  Sprint Bootcamp Day 1
October 10  5:30 – 8:30 PM  Sprint Bootcamp Day 2
November 7  5:30 – 8:30 PM  Pitch Feedback Sessions
December 14  5:30 – 8:30 PM  Final Pitches

Bootcamp topics include problem scoping, value generation models, human-centered design, challenge overview with key stakeholders, health systems, emerging technologies, strategic frameworks, stakeholder mapping, value analysis, implementation planning, and project management.
**Access in-depth data free of charge to Make Your Impact on Childhood Cancer!**

Are you a researcher or do you know a researcher who may be interested in accessing in-depth data related to childhood cancer free of charge?

The Cancer in Young People in Canada (CYP-C) program of the Public Health Agency of Canada has recently released a new infographic on Canada.ca that may be of interest to you and/or your networks.

The new infographic provides an overview of how researchers can apply for and access in-depth data free of charge from the CYP-C program’s national surveillance and research database which contains detailed information about the diagnosis, treatment, and outcomes of every patient cared for by the 17 pediatric oncology centres in Canada from 2001 onwards.

If you have feedback or questions, please contact us at PHAC.chronic.publications-chronique.ASPC@canada.ca.

**CRC Tier 2 Positions in the Faculty of Health Sciences**

McMaster University is located on the traditional territories of the Haudenosaunee and Mississauga Nations and within the lands protected by the “Dish With One Spoon” wampum agreement. In keeping with its Statement on Building an Inclusive Community with a Shared Purpose, McMaster University has a vision to achieve creativity, innovation and excellence in teaching, research and service by engaging a diverse and highly talented educational community and embodying the values of integrity, respect and collaboration.

**Position Description:**

The Faculty of Health Sciences invites applications for an open competition for two Tier 2 CRCs in all fields of study within the faculty. Nominees for Tier 2 Chair positions should, at a minimum, be assistant or associate professors, or possess the necessary qualifications to be appointed to these levels and must hold a full-time faculty appointment at McMaster University within the Faculty of Health Sciences. Individuals who have a firm offer of employment in one of these categories to the University that takes effect by January 1, 2020, are also eligible.

**Tier 2 Chairs**, tenable for five years and renewable once, are intended for exceptional emerging researchers (i.e., candidates must have been an active researcher in their field for fewer than 10 years at the time of nomination) and acknowledged by their peers as having the potential to lead in their field. Tier 2 nominees must:

- be excellent emerging world-class researchers who have demonstrated particular research creativity;
- have demonstrated the potential to achieve international recognition in their fields in the next five to ten years;
- as chairholders, have the potential to attract, develop and retain excellent trainees, students and future researchers; and
- be proposing an original, innovative research program of high quality.

Candidates who are more than 10 years from having earned their highest degree and who have had career breaks, such as maternity, parental, or extended sick leave, clinical training, etc., may have their eligibility for a Tier 2 Chair assessed through the program’s Tier 2 justification process. Please contact Tracy Arabski at arabski@mcmaster.ca for more information. Full program information, including further details on eligibility criteria, can be found at the Canada Research Chairs website at http://www.chairs-chaires.gc.ca/program-programme/nomination-mise_en_candidature-eng.aspx. All nominations for CRCs are subject to review and final approval by the CRC Secretariat.

**Commitment to Inclusive Excellence: Equity, Diversity and Inclusion Statement:**

The diversity of our community and our workforce is integral to and at the core of our innovation and creativity and strengthens our research, teaching and service excellence, as well as our broader learning environment. To achieve this vision for inclusive excellence, McMaster is committed to principles of equity and inclusion. McMaster invites applications from all qualified candidates and particularly welcomes applications from self-identified Indigenous (First Nations, Métis and Inuit).
peoples, members of racialized communities (“visible minorities”), persons with disabilities, women and LGBTQ+ persons of marginalized sexual orientation and gender identities.

All qualified candidates are encouraged to apply; however, in accordance with Canadian Immigration requirements, Canadian citizens and permanent residents of Canada will be given priority.

How to apply:

The application and review process requires interested applicants to complete the “Application to be nominated for a Canada Research Chair” which reflects all criteria and indicators of success and include a most recent CV. The deadline for submission for this competition is September 30th, 2019. The Dean will have final approval of all recommendations regarding CRC allocations. A CRC review panel will review applications and successful applicants will be invited to complete a full application to CRC. Applicants will be notified of their success and the successful applicant will be asked to submit their CRC application based on the time of the expiry of the CRC as outlined below.

<table>
<thead>
<tr>
<th>Tier 2 CRC</th>
<th>Date of Internal Application to be nominated for a Tier 2 Canada Research Chair</th>
<th>Anticipated Date of Approval FHS Committee</th>
<th>Date of Application to CRC</th>
<th>Anticipated Date of Decision from CRC</th>
<th>Commencement of New Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two Tier 2 CRCs</td>
<td>September 30th, 2019</td>
<td>November 30th, 2019</td>
<td>April 20th, 2020</td>
<td>October 2020</td>
<td>October 1st, 2020</td>
</tr>
</tbody>
</table>

McMaster University recognizes the potential impact that career interruptions and personal circumstances (e.g., pregnancy, early childcare, eldercare, illness, etc.) can have on an applicant’s record of research achievement. We encourage applicants to explain in their applications the impact that career interruptions, or other issues may have had as described under “Career Interruptions” at CRC’s Requirements for recruiting and nominating Canada Research Chairs at http://www.chairs-chaires.gc.ca/program-programme/equity-equite/recruitment-recrutement-eng.aspx. Further detail may be found under Guidelines for Assessing the Productivity of Nominees at http://www.chairs-chaires.gc.ca/peer_reviewers-evaluateurs/productivity-productivite-eng.aspx#career.

Applicants should submit the application to be nominated for a CRC chair, cv, and a statement describing any contributions that the applicant may have made to advancing equity, diversity and inclusion in teaching, learning, research or service within post-secondary, community-based and other professional settings (2 pages maximum).

All applicants must also complete a brief Diversity Survey as part of the application process. This survey can be found at https://surveys.mcmaster.ca/limesurvey/index.php/77732?lang=en and will take approximately two minutes to complete. The questions are voluntary. All information collected is confidential and will be used to support efforts to broaden the diversity of the applicant pool and to promote a fair, equitable and inclusive talent acquisition process.

Job applicants requiring accommodation to participate in the hiring process should contact the Human Resources Service Centre at 905-525-9140 ext. 222-HR (22247) to communicate accommodation needs.

Queries should be addressed to Tracy Arabski, Director, Health Research Services at arabski@mcmaster.ca or ext. 22515.

New Frontiers in Research Fund

Exploration stream

All competition documents are available on the program website and the Convergence Portal is open. New this year, researchers at all career stages are invited to apply to the program. The objective of the Exploration stream is to generate opportunities for to conduct high-risk, high-reward and interdisciplinary research not available through funding opportunities
currently offered by the three agencies.

**Application Deadlines:**
Applications at each stage will be submitted by the RGO (HRS/ROADS depending on PI’s primary departmental affiliation):
- Application stage, for those invited, has a deadline of December 10th, 2019 (at 8:00 PM eastern). Internal deadline is November 26th, 2019.

**Introducing NSERC’s New Research Partnership Program now called Alliance Grants**

NSERC has announced the launch of the new research partnerships program, now called Alliance Grants. This program will replace the CRD, Engage (and Engage Plus), IRC, Strategic Partnership (Projects and Networks), Experience and Connect grants.

Please note the following:
- NSERC will begin accepting new applications for Option 1 of this program (NSERC funds 50-66% of the project depending on the size of the partner) as of May 21st, 2019
- Option 2 (NSERC funds 90-100% of the project) will be phased in gradually
- All currently awarded projects will have no changes

If you have any questions regarding NSERC’s new Alliance grant, please contact:
Amber Metham
Associate Director, Research Contracts
McMaster Industry Liaison Office
metham@mcmaster.ca, ext. 26878

MILO will be preparing documents to assist researchers with applications to the new program and will be circulating those in the near future.

**2020-2021 Fulbright Canadian Research Chair Program**

Fulbright Scholars are selected for their academic merit, leadership potential and interest in engaging with international scholars and communities. These grants support research with colleagues at institutions across the US.
For a full list of Fulbright opportunities see the link here: [https://www.fulbright.ca/programs/canadian-scholars/visiting-chairs-program](https://www.fulbright.ca/programs/canadian-scholars/visiting-chairs-program)

Eligibility for these awards, require the candidate to meet the minimum requirements mentioned below:
- Have Canadian citizenship (Permanent residence is not sufficient).
- Hold a PhD or equivalent professional/terminal degree as appropriate.
- Be proficient in English.
- Applications accepted until November 15, 2019
- For a more comprehensive overview of the application process, please access this link.

**Fulbright Canada Research Chair in Public Health**- Johns Hopkins University- US$25,000 for 4 months.

**Funding opportunities for southern Ontario organizations**

On February 27, 2019, [over $1 billion was announced](https://www.feddev.com) for FedDev Ontario to continue driving innovation and growth in the region over the next six years. FedDev Ontario is dedicating $100 million of this new funding to support projects in rural southern Ontario.

FedDev Ontario is now accepting applications under three simplified funding streams that are easy to navigate, and have been designed to meet the needs of our innovators, job creators and communities.
FedDev Ontario is looking for innovative projects in southern Ontario that will:

- Increase the number of high-growth firms.
- Strengthen key clusters and build on areas of regional innovation strength.
- Increase the commercialization of new and innovative technologies, products or processes.
- Increase business investments in the adoption/adaptation of leading-edge technologies.
- Create and maintain highly skilled jobs.
- Increase the value of exports.
- Promote inclusive growth and participation of traditionally underrepresented groups such as women, Indigenous and young entrepreneurs.
- Strengthen opportunities and networks to drive growth, and support the attraction and retention of businesses and talent to southern Ontario’s smaller communities and rural areas.

Applications can be submitted for:

- Non-repayable contributions from $250,000 up to $5 million per project for not-for-profit organizations.
- No interest, repayable contributions from $250,000 up to $5 million per project for incorporated businesses, including Indigenous businesses.

Explore our funding opportunities by clicking here and choosing one of three funding streams.

### MIRA 2019 Funding

**RESEARCH GRANTS**

**MIRA/LCMA Matching Funding for External, Competitive Funding Calls**

**Deadline:** Rolling

**Funding available:** Matching funds up to $100,000

In order to improve the positioning of McMaster’s researchers in external funding competitions, MIRA and the Labarge Centre for Mobility in Aging have allocated funding that may be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component. For more details, click here.

### Compilation of GDPR Guidance Now Available

The Office for Human Research Protections has developed a new resource for IRBs, researchers, and sponsors that are involved in human subjects research in Europe. Titled Compilation of European GDPR Guidances, the document lists the data protection authorities of all European countries that fall under the new E.U. General Data Protection Directive (GDPR). For each country, the compilation also provides the links to any general GDPR guidances, as well as specific guidances on the topics of Research, Legal Basis, Consent, and International Data Transfer.

The new Compilation is available here: [https://www.hhs.gov/ohrp/international/index.html](https://www.hhs.gov/ohrp/international/index.html)

### Health Research Grant Competitions

*Programs administered by Health Research Services, unless otherwise indicated. Email: hsresadm@mcmaster.ca*

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIHR – Fellowship</td>
<td>e-approval</td>
<td>Graduate Studies</td>
<td>Oct 1</td>
</tr>
<tr>
<td>CIHR – Operating Grant: Spread and Scale of Existing Community-Based Primary Healthcare and eHealth Innovations</td>
<td>Oct 1</td>
<td></td>
<td>Oct 15</td>
</tr>
<tr>
<td>CIHR – Prize: The CIHR Institute of Human Development, Child and Youth Health Talks</td>
<td>Oct 1</td>
<td></td>
<td>Oct 15</td>
</tr>
<tr>
<td>CIHR – Catalyst Grant: HIV/AIDS and STBBI Community-Based Research</td>
<td>Oct 3</td>
<td>Oct 17</td>
<td></td>
</tr>
<tr>
<td>CIHR – Doctoral Research Award: Doctoral Foreign Study Award</td>
<td>Graduate Studies</td>
<td>Oct 17</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: HIV/AIDS and STBBI Community-Based Research</td>
<td>Oct 3</td>
<td>Oct 17</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: Patient-Oriented Research Impact Assessment Grants</td>
<td>Oct 8</td>
<td>Oct 22</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: Women’s Health Clinical Mentorship Grant</td>
<td>Oct 8</td>
<td>Oct 22</td>
<td></td>
</tr>
<tr>
<td>CIHR – Operating Grant: Pediatric REB Initiative</td>
<td>Oct 31</td>
<td>Nov 14</td>
<td></td>
</tr>
<tr>
<td>CIHR – Fellowship: Patient-Oriented Research Awards – Transition to Leadership Stream – Phase 1</td>
<td>Oct 31</td>
<td>Nov 14</td>
<td></td>
</tr>
<tr>
<td>CIHR – Doctoral Research Award: Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award</td>
<td>e-approval</td>
<td>Graduate Studies</td>
<td></td>
</tr>
<tr>
<td>“NEW” CIHR – Masters Award: Frederick Banting and Charles Best Canada Graduate Scholarships</td>
<td>Graduate Studies</td>
<td>Dec 2</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: Personalized Health</td>
<td>Oct 8</td>
<td>March 24 2020</td>
<td>April 7 2020</td>
</tr>
</tbody>
</table>

### Funding Opportunity (Non-CIHR)

<table>
<thead>
<tr>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct 1</td>
<td>Oct 15</td>
<td></td>
</tr>
<tr>
<td>Oct 3</td>
<td>Oct 15</td>
<td></td>
</tr>
<tr>
<td>Oct 8</td>
<td>Oct 22</td>
<td></td>
</tr>
<tr>
<td>Oct 14</td>
<td>Oct 28</td>
<td></td>
</tr>
<tr>
<td>Oct 17</td>
<td>Oct 31</td>
<td></td>
</tr>
<tr>
<td>Oct 17</td>
<td>Oct 31</td>
<td></td>
</tr>
<tr>
<td>Oct 17</td>
<td>Oct 31</td>
<td></td>
</tr>
<tr>
<td>Oct 17</td>
<td>Oct 31</td>
<td></td>
</tr>
<tr>
<td>Oct 21</td>
<td>Nov 4</td>
<td></td>
</tr>
<tr>
<td>Oct 21</td>
<td>Nov 4</td>
<td></td>
</tr>
<tr>
<td>Oct 24</td>
<td>Nov 8</td>
<td></td>
</tr>
<tr>
<td>Oct 24</td>
<td>Nov 8</td>
<td></td>
</tr>
<tr>
<td>Oct 30</td>
<td>Nov 13</td>
<td></td>
</tr>
<tr>
<td>Nov 1</td>
<td>Nov 15</td>
<td></td>
</tr>
<tr>
<td>Nov 1</td>
<td>Nov 15</td>
<td></td>
</tr>
<tr>
<td>Nov 15</td>
<td>Nov 29</td>
<td></td>
</tr>
<tr>
<td>Nov 15</td>
<td>Nov 29</td>
<td></td>
</tr>
<tr>
<td>Nov 15</td>
<td>Nov 29</td>
<td></td>
</tr>
<tr>
<td>Nov 15</td>
<td>Nov 29</td>
<td></td>
</tr>
<tr>
<td>Nov 25</td>
<td>Dec 9</td>
<td></td>
</tr>
<tr>
<td>Nov 29</td>
<td>Dec 13</td>
<td></td>
</tr>
</tbody>
</table>

*NEW* indicates new opportunities.
<table>
<thead>
<tr>
<th>Program</th>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex's Lemonade Stand: Epidemiology Grants</td>
<td>Dec 2</td>
<td>Dec 16</td>
</tr>
<tr>
<td>Alex's Lemonade Stand: Young Investigator Grants</td>
<td>Dec 2</td>
<td>Dec 16</td>
</tr>
<tr>
<td>Alex's Lemonade Stand: Crazy 8 Initiative</td>
<td>Oct 1</td>
<td>Jan 20 2020</td>
</tr>
<tr>
<td>Leukemia &amp; Lymphoma Society: Specialized Centre of Research Program</td>
<td>Oct 1</td>
<td>Feb 28 2020</td>
</tr>
<tr>
<td>Alex’s Lemonade Stand: Innovation Grants</td>
<td>Nov 4</td>
<td>March 23 2020</td>
</tr>
<tr>
<td>Society of Facioscapulohumeral Muscular Dystrophy: Research Grant</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>National Multiple Sclerosis Society: Pilot Research Grants</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Alex’s Lemonade Stand: RUNX1 Early Career Investigator Grant</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Canadian Cancer Society: Travel Awards</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Canadian Cancer Society: Junior Investigator Grant Panel Travel Award</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>SickKids Foundation: Community Conference Grants</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Cancer Research Society: Translational Research Partnership Program</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>HHS: Clinical Health Professional Travel Awards</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>The Ontario HIV Treatment Network (OHTN), Endgame Funding Program:</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Community-Based Research and Evaluation (CBR&amp;E) Awards</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Ontario Brain Institute (OBI): Event Funding Program</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Crohn’s &amp; Colitis Foundation: IBD Ventures</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Ontario Genomics: Genomic Applications Partnership Program (GAPP)</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Weston Brain Institute Postdoctoral Scholars at Oxford</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Weston Brain Institute International Fellowships: Canada</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Alzheimer’s Drug Discovery Foundation: Drug Discovery Program</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Alzheimer’s Drug Discovery Foundation: Neuroimaging &amp; CSF Biomarker</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Development Program</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>McMaster University, McMaster Institute for Research on Aging (MIRA),</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Canadian Longitudinal Study on Aging (CLSA): Call for Proposals</td>
<td></td>
<td>MIRA</td>
</tr>
<tr>
<td>McMaster University, McMaster Institute for Research on Aging (MIRA),</td>
<td></td>
<td>MIRA</td>
</tr>
<tr>
<td>Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Opportunities</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>MITACS Globalink Research Award</td>
<td></td>
<td>MILO</td>
</tr>
<tr>
<td>MITACS Accelerate Fellowship</td>
<td></td>
<td>MILO</td>
</tr>
<tr>
<td>Weston Brain Institute: Big Ideas</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Weston Brain Institute: Early Phase Clinical Trials: Canada</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>OCE Voucher for Innovation and Productivity II (VIP II) Program</td>
<td></td>
<td>MILO</td>
</tr>
<tr>
<td>MITACS Accelerate Program</td>
<td></td>
<td>MILO</td>
</tr>
</tbody>
</table>
**Funding Opportunity (DoD)**

(eBRAP account required – must be validated by McMaster prior to any submission)

<table>
<thead>
<tr>
<th>Funding Opportunity (DoD)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Defense (DoD) Combat Readiness-Medical Research Program (CRRP): Rapid Development and Translational Research Award</td>
<td>Oct 23</td>
<td>Oct 30</td>
<td>Nov 13</td>
</tr>
</tbody>
</table>

### CIHR – Fellowship

Fellowships provide support for highly qualified applicants in all areas of health research at the post-PhD degree or post-health professional degree stages to add to their experience by engaging in health research either in Canada or abroad.

Additional funds are available through this competition to support Fellowship award applications in the following specific research areas:

- Fellowship: Fall 2019 Priority Announcements (Specific Research Areas)

**Funding Details:** The maximum amount awarded for a single award is up to $60,000 per annum for up to 5 years. The value and duration of each award is determined by the degree(s) held, licensure (where applicable), location of tenure and experience of the applicant.

**Additional Details**

This competition is an e-approval competition managed on ResearchNet (RNet) and is being managed by the Office of Postdoctoral Affairs in the School of Graduate Studies. Applicants are encouraged to contact OPART at postdoc@mcmaster.ca for questions regarding required paperwork, deadlines and online submissions. Sponsor assessments are required AHEAD of any deadlines; it is the applicant’s sole responsibility to follow up with his/her sponsors to ensure that the assessments are submitted online by their sponsors no later than Saturday, September 28, 2019 8:00am.

**INTERNAL Deadline:** September 30, 2019 on ResearchNET by 8:00 AM  
**Sponsor Deadline:** October 1, 2019  
*To apply please contact Graduate Studies*

### CIHR – Operating Grant: Spread and Scale of Existing Community-Based Primary Healthcare and eHealth Innovations

Since 2010, CIHR has invested over $584M in research projects in the areas of community-based primary health care (CBPHC) and eHealth. Throughout this timeframe, the Institute of Health Services and Policy Research (IHSPR), in partnership with several other CIHR Institutes, led two major initiatives in these areas, namely, Community-Based Primary Health Care and eHealth Innovations. Both of these initiatives had flagship programs that centered on improving health outcomes and care delivery through the development and evaluation of models of care and/or eHealth innovations.

The Institute of Health Services and Policy Research is dedicated to supporting innovative research and catalyzing the application of these research findings to policies, practice and programs that provide real-world benefit and enhance the provision of high-quality care for Canadians. However, very often funded projects and programs are implemented successfully in one jurisdiction without attention to the possibility of scaling and spreading beyond.

The goal of this funding opportunity is to support research teams to develop strategies on how to successfully adapt approaches and/or interventions that are known to improve the health of Canadians to new sites, settings, and/or populations.

Research teams will use the funds to develop a clearly articulated plan to equitably scale and spread the successful approaches or interventions to new sites, new settings, or new populations. The spread plan must describe the successful approach or intervention and the expected improvements in health outcomes. The spread plan must also describe the current setting where the innovation is successfully implemented, the factors that contributed towards success, including key stakeholders involved, along with a description of the new site, setting, or population where the innovation will be implemented, the key stakeholders that will need to be involved, and address how contextual factors may differ between the two. Furthermore, the strategy should identify any implementation facilitators and barriers and note the approaches that will be used to overcome any encountered obstacles. Teams must also work towards developing an evaluation plan that would be used to assess the implementation and impact of the approach or intervention.

In order to accelerate the spread and scale of successful approaches and interventions, researchers must collaborate with decision makers who have the capacity to move knowledge into action in terms of implementing the approach or intervention to a new site or new setting, or to a new population.

**Funding Details:** The maximum amount per grant is $70,000 per year for up one (1) year.
CIHR – Prize: The CIHR Institute of Human Development, Child and Youth Health Talks

The CIHR Institute of Human Development, Child and Youth Health (IHDCYH) is launching its sixth round of the IHDCYH Talks Video Competition, a unique opportunity to submit short videos (5 minutes or less) sharing evidence-based messages in the area of maternal, reproductive, child and youth health. This competition encourages the production of videos that present a clear evidence-based message to a lay audience that is designed to have a positive impact on the health of children, youth and families.

This competition is soliciting videos not just from members of the research community, but also more widely, from non-governmental or not-for-profit organizations (including community or charitable organizations), as well as members of the general public who are able to demonstrate a clear, evidence-based message related to IHDCYH's mandate.

Successful videos will be posted on CIHR and IHDCYH social media and shared through other communications channels. It is important that the content be engaging, easily understood and accessible to a lay audience. For information on the IHDCYH Talks program, and to view the videos from past competition winners, see the IHDCYH Talks webpage.

**Funding Details:** The total amount available for this funding opportunity is $5,500, enough to fund four prizes. Of this $5,500:

- $3,000 is available to fund 1 first place prize
- $1,000 is available to fund 1 runner-up prize
- $1,500 is available to fund 2 specially commended prizes of $750 each.

CIHR – Catalyst Grant: HIV/AIDS and STBBI Community-Based Research


The FI is leading efforts towards implementing interventions developed with distinct communities and the CBR Program aligns with these directions. With the release of the [Pan-Canadian Sexually Transmitted and Blood-Borne Infections (STBBI) Framework for Action](https://www.hivcommons.ca), the FI will expand its scope to promote an integrated approach toward addressing HIV and other STBBI. HIV and other STBBI share common risk factors and transmission routes; are exacerbated by the social, structural, economic and environmental contexts and experience of inequity; and interact with each other to negatively impact disease trajectories and enhance vulnerability. Given the synergies that exist between HIV and other STBBI, the HIV/AIDS research initiative strongly encourages the incorporation of an integrated approach to addressing HIV and other STBBI, while recognizing that infection-specific approaches are still appropriate in certain circumstances or communities. In addition, the HIV/AIDS research initiative strongly emphasizes the importance of meaningful engagement of those with lived/living experience to guide the research processes to better inform research methods and outcomes, which is in keeping with the objectives of the CBR Catalyst Grants.

The CIHR HIV/AIDS CBR Program supports the partnered work of Community Leaders and Researchers in knowledge development and capacity-building initiatives of relevance to communities engaged in the fight against HIV/AIDS. The CIHR HIV/AIDS CBR Program encourages incorporation of other STBBI into the research framework, but will fund project for which HIV/AIDS remain the main focus. All opportunities offered through the CBR Program are available in two distinct funding streams: Indigenous and General.

The aim of the Catalyst Grant component of the CBR program is to provide seed money to support HIV/AIDS CBR research activities which represent a first step towards the pursuit of more comprehensive funding opportunities (e.g., operating grants).

**Funding Details:** The maximum amount per grant is $40,000 for up to one year. Of this $480,000:

- $240,000 is available to fund six applications relevant to the General Stream.
- $240,000 is available to fund six applications relevant to the Indigenous Stream.
- Note that should a stream run out of fundable applications but have funds remaining, these funds can be transferred to the other stream.
**CIHR – Doctoral Research Award: Doctoral Foreign Study Award**

The Doctoral Foreign Study Award (DFSA) program supports high-calibre students engaged in doctoral programs in all academic disciplines who are pursuing a doctoral degree in a health-related field abroad.

**Funding Details:** The maximum amount per award is $35,000 per year for up to three (3) years. Award funding is allocated as follows:

- Stipend: $30,000 per annum
- Research Allowance: $5,000 per annum

**Additional Details**

**Sponsor Deadline:** October 17, 2019

*To apply please contact Graduate Studies*

---

**CIHR – Operating Grant: HIV/AIDS and STBBI Community-Based Research**

The [CIHR HIV/AIDS Community-Based Research (CBR) Program](#) is one of four research funding areas of the [CIHR HIV/AIDS Research Initiative](#). The CIHR HIV/AIDS Research Initiative is responsible for the research components of the major Government of Canada initiative in HIV/AIDS, namely the [Federal Initiative to Address HIV/AIDS in Canada (FI)](#).

The FI is leading efforts towards implementing interventions developed with distinct communities and the CIHR CBR Program aligns with these directions. With the release of the [Pan-Canadian Sexually Transmitted and Blood-Borne Infections (STBBI) Framework for Action](#), FI will expand its scope to promote an integrated approach toward addressing HIV and other STBBI. HIV and other STBBI share common risk factors and transmission routes; are exacerbated by the social, structural, economic and environmental contexts and experience of inequity; and interact with each other to negatively impact disease trajectories and enhance vulnerability. Given the synergies that exist between HIV and other STBBI, the HIV/AIDS research initiative strongly encourages the incorporation of an integrated approach to addressing HIV and other STBBI, while recognizing that infection-specific approaches are still appropriate in certain circumstances or communities. In addition, the HIV/AIDS research initiative strongly emphasizes the importance of meaningful engagement of those with lived/living experience to guide the research processes to better inform research methods and outcomes, which is in keeping with the objectives of the CBR Operating Grants.

The CIHR HIV/AIDS CBR Program supports the partnered work of Community Leaders and Researchers in knowledge development and capacity-building initiatives of relevance to communities engaged in the fight against HIV/AIDS. The CIHR HIV/AIDS CBR Program encourages incorporation of other STBBI into the research framework, but will fund projects for which HIV/AIDS remain the main focus. All opportunities offered through the CBR Program are available in two distinct funding pools: Indigenous and General.

The aim of the Operating Grant component of the CBR Program is to contribute to the creation, dissemination and use of health-related knowledge, and to help develop research capacity, by supporting original, high-quality projects proposed and conducted in partnership with the community and academia.

**Funding Details:** The maximum amount per grant is $150,000 per year for up to three years for a total of $450,000, per grant. Of this $1,800,000:

- $900,000 is available to fund two applications relevant to the General Stream.
- $900,000 is available to fund two applications relevant to the Indigenous Stream.
- Note that should a stream run out of fundable applications but have funds remaining, these funds can be transferred to the other stream.

**Additional Details**

**Internal HRS Deadline:** October 3, 2019

**Sponsor Deadline:** October 17, 2019

---

**CIHR – Operating Grant: Patient-Oriented Research Impact Assessment Grants**

The [Strategy for Patient-Oriented Research (SPOR)](#) is a national coalition of federal, provincial and territorial partners (patients and informal caregivers, provincial health authorities, academic health centres, charities, philanthropic organizations, private sector, etc.) dedicated to the integration of research into care.

Patient-oriented research refers to a continuum of research that engages patients as partners, focusses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with relevant stakeholders, aims to apply the knowledge generated to improve healthcare systems and practices.
While patient-oriented research is considered a relatively recent culture shift, many countries, including Canada, have been making investments in this approach to health research for a number of years. SPOR, as one example, represents a large collective endeavor by many stakeholders and carries great expectation for return on investment. Such returns refer to health, social and/or economic benefits or impacts. ‘Health impacts’ can be defined as changes in the healthy functioning of individuals (physical, psychological, and social aspects of their health), changes to health services, or changes to the broader determinants of health. ‘Social impacts’ are changes that are broader than simply those to health noted above, and include changes to working systems, ethical understanding of health interventions, or population interactions. ‘Economic impacts’ can be regarded as the benefits from commercialization, the net monetary value of improved health, and the benefits from performing health research (Académie canadienne des sciences de la santé, 2011).

The Patient-Oriented Research Impact Assessment Grants aim to build capacity in Canada to conduct patient-oriented research impact assessments and to generate evidence of the impact of patient-oriented research to date. Impact assessment methods should seek to capture the wide diversity of health, social and economic impact, including better-informed public policy and decision making. Applicants are encouraged to reference the guidance and data sources outlined in the Additional Information section below.

Funding Details: The maximum amount per grant is $50,000 per year for up to one year. Applicants are not required to secure partner contributions to match the CIHR contribution.

Additional Details
Internal HRS Deadline: October 8, 2019
Sponsor Deadline: October 22, 2019

**CIHR – Operating Grant: Women’s Health Clinical Mentorship Grant**

The purpose of this funding opportunity is to advance clinical research in women’s health and to build capacity in the next generation of women’s health clinician-researchers. The aim is for trainees, students or residents to be paired with and mentored by a women’s health clinician-specialist on a one-year research project with the goal of improving clinical care.

The research question(s) must:

- focus on the health of women. For the purpose of this grant, women is a term used to include biological females AND any other individuals who identify as women; and
- focus on one or more of the following research areas:
  - Menarche and/or menopause;
  - Gynecology;
  - Pelvic health/urogynecology;
  - Off-label testosterone treatment for women experiencing hypoactive sexual desire; and/or
  - Cross-hormone replacement therapies for individuals undergoing gender-affirming treatments.

Funding Details: The maximum amount per grant is $50,000 for one (1) year.

Additional Details
Internal HRS Deadline: October 8, 2019
Sponsor Deadline: October 22, 2019

**CIHR – Operating Grant: Pediatric REB Initiative**

Investigators developing multi-site research studies in Canada often encounter challenges with gaining the Research Ethics Board (REB) approvals required, in particular where such studies are planned across more than one province. This can delay initiation of multi-jurisdiction research studies in Canada, increase the financial burden of conducting research, and compromise accrual of patients. Such delays in the overall initiation of research studies reduce the ability of Canadians to compete in the international arena and may ultimately lead some sponsors to conduct research outside of Canada.

These challenges are particularly acute in pediatric studies, where small sample sizes/patient populations at individual institutions exponentially increase the need for studies to be multi-site and multi-jurisdictional. This is especially true for inherited/rare diseases. Pediatric studies also have unique challenges around considerations such as consent vs. assent and privacy. However, the pediatric community offers a significant advantage in this situation, representing a well-defined community, with significant awareness of the key issues and a strong cross section of the relevant expertise.

In response to these challenges and assets, the CIHR Institute of Human Development, Child and Youth Health (CIHR-IHDCYH) and the CIHR Institute of Genetics (CIHR-IG) are developing an initiative to promote child health research through a collaborative approach to a streamlined ethics review. During the early development of this initiative (October to December 2018), CIHR-IHDCYH
conducted a series of consultations with research leadership and ethics experts from across the Canadian tertiary Children’s hospitals and research institutes, as well as with government representatives in provinces where the mandate for research ethics review is held at that level. CIHR-ICHDCYH then hosted a Community & Stakeholder Engagement Workshop in January 2019 to bring together the research and administrative leadership, and ethics expertise identified during the consultations. More than 50 delegates attended this workshop, with balanced representation from the research, administrative and ethics domains of each of the Children’s hospitals and research institutes across Canada, as well as Health Canada and provincial government representatives.

Through the discussion and subsequent collaborative review of the resulting workshop report, key concepts were identified as essential underpinnings of the process to work toward a streamlined ethics review process with the goal of achieving a single review accepted by all participating sites:

- The process should be designed to support progression towards delegation of acceptance of a review, in a predictable and timely manner that nonetheless retains a high standard of rigor.
- To support this process, the ethics review should be separated to the greatest extent possible from the other parts of the approval and authorization process, including operational, science, and contractual pieces.
- Successful establishment and uptake will require a collaborative process that engages with groups according to their states of readiness, that is mindful of differences in provincial process and needs, and that supports the development of trust between REBs.
- Engagement will need to be broad to ensure that all relevant stakeholders are involved, including ethics and jurisdictional legal expertise, and expertise in REB process, as well as research and administrative leadership. This will support both the development of the delegated process, as well as processes to address emerging areas such as regulatory requirements for innovative therapies (including trial designs), genomic medicine and multi-source data integration.
- The development of a platform with a single point of contact would likely achieve the goal of a streamlined ethics review process. For instance, the platform would support socialization of standardized practices.
- A key element underpinning the successful socialization of the research support infrastructure would be the development of education pieces for both the researchers developing REB applications, and for REB Chairs/Members.

The development of research support infrastructure that incorporates these key concepts will provide an invaluable opportunity for pediatric research in Canada. It is anticipated that this will be a pilot initiative that will be scalable to support other research areas and could underpin a key piece of research support infrastructure to enable health research in Canada.

**Funding Details:** The total amount available for this funding opportunity is $2,500,000, enough to fund one grant. The maximum amount for this grant is $500,000 per year for up to five years for a maximum total of $2,500,000.

**Additional Details**

**Internal HRS Deadline:** October 31, 2019  
**Sponsor Deadline:** November 14, 2019

---

**CIHR – Fellowship: Patient-Oriented Research Awards – Transition to Leadership Stream – Phase 1**

The **Strategy for Patient-Oriented Research (SPOR)** is a national coalition of federal, provincial and territorial partners (patients and informal caregivers, provincial health authorities, academic health centres, charities, philanthropic organizations, private sector, etc.) dedicated to the integration of research into care.

Patient-oriented research refers to a continuum of research that engages patients as partners, focusses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with relevant stakeholders, aims to apply the knowledge generated to improve healthcare systems and practices.

**Funding Details:** The total amount available for this funding opportunity is $4,650,000, enough to fund approximately twenty (20) awards. This amount may increase if additional funding partners participate.

Of this $4,650,000:

- $3,487,500 is available to fund up to fifteen (15) awards in the Transition to Leadership General Pool.
- $1,162,500 is available to fund up to five (5) awards relevant to the Indigenous Peoples’ Health Pool.
- The maximum amount per year for trainees pursuing graduate training is $55,000, for two to three years*.

Of this $55,000:
- Stipend: $50,000 per annum
- Research allowance: $5,000 per annum
- The maximum amount per year for trainees pursuing post-doctorate training is $77,500, for two to three years*.
Of this $77,500:

- Stipend: $70,000 per annum
- Research allowance: $7,500 per annum
- Phase 1 does NOT require 1:1 matching of CIHR funds; however, applicants should note that Phase 2 will require 1:1 matching contributions from partners.

* During the application process, the Nominated Principal Applicant will be required to choose a fixed duration for each Phase of their six-year award. Applicants will no longer be able to adjust the duration once it has been chosen. (For example, an applicant may choose to spend three years as a trainee in Phase 1 and three years as an independent researcher in Phase 2; alternatively, an applicant may choose to spend only two years in Phase 1 and have four years of funding in Phase 2**.

** The amount of funding per Phase 2 award is $115,000 per annum and requires 1:1 matching contributions from partners.

**Additional Details**

**Internal HRS Deadline:** October 31, 2019  
**Sponsor Deadline:** November 14, 2019

**CIHR – Doctoral Research Award: Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Award**

The Canada Graduate Scholarship Doctoral (CGS D) program supports high-calibre students engaged in doctoral programs in all academic disciplines. This support allows scholars to fully concentrate on their doctoral studies, to seek out the best research mentors in their chosen fields and contribute to the Canadian research ecosystem during and beyond the tenure of their awards.

For detailed information, visit the [harmonized CGS D program page](#).

**Funding Details:** The maximum amount per award is $35,000 per year for up to three (3) years. Award funding is allocated as follows:

- Stipend: $30,000 per annum  
- Research Allowance: $5,000 per annum

**Additional Details**

**Sponsor Deadline:** November 21, 2019  
*To apply please contact Graduate Studies*

**CIHR – Masters Award: Frederick Banting and Charles Best Canada Graduate Scholarships**

The Canada Graduate Scholarships Master’s (CGS M) awards are intended to provide special recognition and support to students who are pursuing a Master’s degree in a health-related field at a Canadian institution. These candidates are expected to have an exceptionally high potential for future research achievement and productivity.

For detailed information, visit the [harmonized CGS M program page](#).

**Funding Details:** The total amount available for this funding opportunity is $9.45M, enough to fund approximately 540 awards. Trainee stipend: $17,500 for 12 months, non-renewable.

**Additional Details**

**Sponsor Deadline:** December 2, 2019  
*To apply please contact Graduate Studies*

**CIHR – Team Grant: Personalized Health**

Building on previous investments, the Personalized Health initiative is focused on creating targeted and tailored interventions with high therapeutic effectiveness that requires an unmatched degree of participation by the patient. It will shift the nature of the patient’s relationship with health-care professionals and will increase the patient’s ability to understand their choices and make informed decisions. Patient autonomy can be enhanced by giving patients access to their own data, tools to better understand their options, and involving them in the decision-making process related to their health care. To achieve this level of personalized health, Canadian data assets (including clinical, genomic, administrative, and social data) must be linked and harmonized to create richer phenotypes, and to accelerate and facilitate personalized treatment that factor in sex (biological factors) and gender (psychosocial factors). The creation of both predictive analytic models that can stratify patients by expected outcome and risk, and the eHealth delivery platforms required for patients and providers to interpret and use the data, will lead to improved real-time, personalized, health care. Overall, this innovative model has the potential to leverage patient data to make predictions in health systems that can directly inform and empower patients, as well as to facilitate and improve care delivery.
There have been major innovations, and there are early signs of implementation in certain areas, but overall implementation of personalized health is still in its infancy. This initiative aims to maximize and leverage previous collaborative investments by driving evidence-based implementation of personalized health innovations to contribute to more cost-effective and sustainable health care. In order to do this, teams may partner with an existing publicly funded health-care delivery organization that has the technological resources and organizational infrastructure needed to implement personalized eHealth demonstration projects. Each team must capture and/or develop methods to capture various sources of patient data (e.g. administrative data, genomic data, clinical data, wearable data, data from patient apps) and will then use predictive analytic models to link, harmonize, and analyze the data with the ultimate goal of predicting personalized health outcomes tailored to individuals/patients. Teams must also implement a personalized eHealth delivery platform that incorporates and demonstrates the predictive modeling in an accessible and meaningful way to patients and providers as a means to improve patient empowerment and facilitate shared decision making. The personalized health innovation projects will be implemented into health-care delivery settings and will be aimed at assessing comparative cost-effectiveness, health outcomes, and patient reported outcome measurements as compared to standard-of-care. In addition, all predictive modeling and all outcomes evaluated must include appropriate sex and gender considerations.

Therefore, research teams must have the capacity to:

- Establish productive partnerships with relevant stakeholders, including health-care delivery organizations, health-care professionals, and patient/family/caregiver partners;
- Facilitate the implementation of successful personalized health innovations, which includes predictive analytic and eHealth components, into health-care delivery organizations and promote their uptake and use among providers and patients; and
- Evaluate the impact, cost-effectiveness, health outcomes and patient-reported outcome measures associated with the implemented personalized health innovation project. The evaluation will generate high-quality evidence that uses standard-of-care as a comparator, to assist in the subsequent integration, spread and scale of successful innovations. Evaluations must be sex- and gender-responsive, accounting for differences across diverse groups of men, women and gender-diverse individuals.

Research teams must investigate the relevant factors that will impact the advancement and application of the proposed research by including an integrated ethical, environmental, economic, legal and social component, which must be closely related to the overall project objectives, deliverables and potential social and/or economic benefits.

In addition, CIHR encourages the inclusion and advancement of underrepresented groups in science as one of the means to enhance excellence in research, training and knowledge translation.

**Funding Details:** The maximum amount per grant is $500,000 per year for up to four (4) years, for a total of $2,000,000 per grant.

**Additional Details**

**LOI Deadline:** October 8, 2019

**Internal HRS Deadline:** March 24, 2020

**Sponsor Deadline:** April 7, 2020

**Canadian Cancer Society: Innovation Grants**

Innovation Grants support the highest quality creative problem solving in cancer research. The goal of the Innovation program is to support the development and testing of transformative, paradigm-shifting concepts and approaches to address problems in cancer research, enhance our understanding of cancer, and generate novel approaches to confront the challenges we face in defeating cancer.

Successfully funded Innovation projects are ideally based on “high risk” ideas that have a strong potential for “high reward”. They are feasible and doable by the applicant(s), but not necessarily based on a significant amount of preliminary data. With a significant emphasis on innovation, this program encourages bold attempts to test novel hypotheses and/or generate new knowledge and/or improvements related to cancer prevention, detection, diagnosis, treatment, and support. Applications are encouraged from across all areas and disciplines of cancer research, as well as from investigators in other disciplines whose ideas are relevant to the field of cancer research.

It is hoped that this program will accelerate the introduction of innovation into the entire cancer research system and contribute to the scientific idea pipeline. Proposals with high scientific merit that are deemed derivative or formulaic, pursue next logical steps, or seek to make incremental advancements are not considered innovative and should not be submitted to this competition. Applicants are also cautioned to avoid overly-ambitious aims or aims that are not clearly connected - significant findings from investigators funded by Innovation Grants may be developed further through a CCS "Innovation to Impact" Grant.

**Funding Details:** Up to $100,000 per year and a maximum of $200,000 per grant.
**Canadian Cancer Society: Innovation to Impact Grants**

This program is designed to support the next phase following a productive Innovation or CBCF research grant, with the goal of working towards or achieving a significant impact on cancer.

The Innovation to Impact (i2I) Grants are designed as the next stage in the funding pipeline for Innovation and CBCF Grants that have completed their original aims and have demonstrated productivity (such as publications or scientific presentations). Note that unexpected findings/outcomes from an Innovation or CBCF grant may be pursued through an i2I grant provided that sufficient data exists to support a compelling rationale for the proposed next steps.

Innovation to Impact Grants (i2I) are intended to support the further development of significant findings from a funded CCS Innovation or CBCF grant.

Applicants are required to articulate significant achievements from the original Innovation/CBCF Grant (i.e., significant new knowledge, publications, intellectual property, technology development, or relevant endpoints) and clearly describe and justify the progression to the new research proposed. In other words, the original grant and i2I proposal must be linked by their overarching goal or objective. Applicants must also describe the potential for impact of the proposed project on cancer.

**Funding Details:** Up to $150,000 per year for up to 3 years, to a maximum of $450,000 per grant.

**Additional Details**

Internal HRS Deadline: October 1, 2019

Sponsor Deadline: October 15, 2019

**Susan G Komen: Training Researchers to Eliminate Disparities Grants**

Disparities researchers anywhere in the world are invited to apply for our Training Researchers to Eliminate Disparities Grants.

TREND Grants are intended to establish and/or to sustain an innovative training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

The research training program should be designed to meet the following goals:

- Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
- Develop novel and creative methods to empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

**Funding Details:** $405,000 direct costs only; $135,000 per year for up to 3 years.

**Additional Details**

Internal HRS Deadline: October 3, 2019

Sponsor Deadline: October 17, 2019

**Ontario Molecular Pathology Research Network – Cancer Pathology Translational Research Grants**

OICR’s [Strategic Plan 2016-2021](#) prioritized the establishment of the Ontario Molecular Pathology Research Network (OMPRN), a Collaborative Research Network focused on enhancing molecular pathology research capacity across the province by:

1. Fostering collaboration and cooperation between Ontario academic pathologists;
2. Increasing the participation of pathologists in high-quality translational cancer research; and
3. Providing opportunities for residents, fellows and early career pathologists to obtain training and mentorship in cancer research.

**Funding Details:** $35,000 for 1 year.

**Additional Details**

Internal HRS Deadline: October 14, 2019

Sponsor Deadline: October 28, 2019
**Canadian Orthopaedic Foundation: J. Édouard Samson Award**

The premier award for orthopaedic research in Canada, the J. Édouard Samson Award, recognizes the best career orthopaedic research over a period of five (5) years or more at a Canadian centre. This award is intended to promote further research by the recipient. The recipient will present his/her research at the Annual General Meeting of the Canadian Orthopaedic Association (presentation opportunity to be determined). The award consists of an educational grant and a personal research grant to be used by the recipient at the Canadian institution where he/she currently resides.

This award is decided based on review and recommendation by the Canadian Orthopaedic Foundation’s Research Committee to the Canadian Orthopaedic Foundation’s Board of Directors.

**Funding Details:** $30,000.

**Additional Details**

**Internal HRS Deadline:** October 17, 2019

**Sponsor Deadline:** October 31, 2019

---

**Canadian Orthopaedic Foundation: Canadian Orthopaedic Research Legacy (CORL) Grant**

The CORL program was founded in 2006 to help ensure the legacy of Canada’s world-class status in orthopaedic research, thereby ensuring orthopaedic patients reap the reward of new techniques and treatments made possible through research grants from this program. The total number of awards each year will be variable, based on available funding.

**Funding Details:** $20,000.

**Additional Details**

**Internal HRS Deadline:** October 17, 2019

**Sponsor Deadline:** October 31, 2019

---

**Biocodex Microbiota Foundation: Call for National Project Canada - Microbiome in Human Health and Diseases**

Biocodex is historically involved in research on gut microbiota.

With a mission of advancing the research and understanding of human microbiota, the Biocodex Microbiota Foundation is calling on inspired researchers at Canadian institutions in the microbiome field to submit proposals for funding their projects. For 2019, the Canadian grant will be awarded to an investigator studying a 1 to 2-year long research project within the topic of microbiome in human health and diseases.

Studies in translational animal models are encouraged.

**Funding Details:** The total grant amount is 25,000 €.

**Additional Details**

**Internal HRS Deadline:** October 17, 2019

**Sponsor Deadline:** October 31, 2019

---

**CoEN 2019 Call for Proposals: Pathfinder 4**

The CIHR Dementia Research Strategy supports research on the latest preventive, diagnostic and treatment approaches to Alzheimer’s disease and other neurodegenerative diseases causing dementia. It consists of an international and a national component, which together, allows the Government of Canada to support world-class research on dementia, contributing to the global pursuit of finding a cure or disease-modifying treatment for dementia by 2025.

The Canadian Consortium on Neurodegeneration in Aging (CCNA) is the Canadian component of the CIHR Dementia Research Strategy representing the Center of Excellence for Canada. CCNA is the premier research hub for all aspects of research involving neurodegenerative diseases that affect cognition in aging – including Alzheimer’s disease.

The Network of Centres of Excellence in Neurodegeneration (CoEN) is an international initiative, which will connect Centers of Excellence (CoEs) with a critical mass of resources and expertise to drive a step-change in neurodegeneration research. As such, the Lead Canadian Principal Applicant for this funding opportunity must be a CCNA member. It is expected that teams will combine the research strengths across CoEs in at least two partner countries to provide a true value-added collaborative effort that will advance our approach to neurodegeneration research. Projects will address issues which would not readily be funded through the standard grant mechanisms of the CoEN partners, and it is expected that in addition to collaboration across CoEs, projects should also serve to provide a platform for future collaboration with industry.
This funding opportunity seeks to address the need for innovative research to underpin new approaches to therapeutic intervention. The call sets out to encourage “outside the box” thinking, to stimulate new and unconventional approaches and creative solutions to the challenges of neurodegeneration research by undertaking high-risk / high-payoff research.

For more information, please consult the Centres of Excellence in Neurodegeneration (CoEN) website.

**Funding Details:** The total amount available for the Canadian portion of this funding opportunity is $666,666, enough to fund approximately two (2) grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $166,666 per year for up to two (2) years for a total of $333,333 per grant.

**Additional Details**

**Internal HRS Deadline:** October 21, 2019  
**Sponsor Deadline:** November 4, 2019

### BrightFocus Foundation: Alzheimer’s Disease Research Grant

**Standard Awards:** The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies.

**Funding Details:** $100,000 per year for a maximum of 3 years.

**Postdoctoral Fellowship Awards:** Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant’s own independent research career.

**Funding Details:** $100,000 per year for a maximum of 2 years.

**Additional Details**

**Internal HRS Deadline:** October 21, 2019  
**Sponsor Deadline:** November 4, 2019

### BrightFocus Foundation: National Glaucoma Research Grant

**Standard Award:** The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies.

**Funding Details:** $100,000 per year for 2 years.

**Additional Details**

**Internal HRS Deadline:** October 24, 2019  
**Sponsor Deadline:** November 8, 2019

### Alzheimer Society: Research Programs

The Alzheimer Society Research Program is looking for big, bold, out-of-the-box ideas to find the causes of dementia and breakthrough solutions in care. We’re investing more in new investigators to spark their ideas and build their careers. We’re looking for candidates across all disciplines who want to tackle the biggest challenge of our time.

**Proof of Concept Grant:** Supports investigators with innovative, high-risk, high-yield approaches to research.

**Funding Details:** $100,000 for up to 5 years.

**New Investigator Operating Grant:** Supports new investigators within the first four years of their first faculty position.

**Funding Details:** $200,000 for up to 4 years.

**Postdoctoral Fellowship:** Supports trainees within the first 18 months of completing their PhD program.

**Funding Details:** $50,000 per year for 2 years.

**Doctoral Award:** Supports students in the first 18 months of their PhD program.

**Funding Details:** $22,000 per year for 3 years.

**Additional Details**

**Internal HRS Deadline:** October 24, 2019
Bill & Melinda Gates Foundation: Innovations for Improving the Impact of Health Campaigns

We are seeking innovative solutions that accelerate the improvement of coverage, reach, efficiency, and effectiveness of health campaigns.

Specifically, we are looking for innovations in approaches, practices, or tools that dramatically improve the planning and microplanning, implementation/operations, and monitoring and evaluation that will lead to improved effectiveness of campaigns.

In order to contribute to the development and spread of campaign "best practices", a solution should be applicable to campaigns beyond the context in which it is originally tested (e.g. applicable in multiple lower- to middle-incomes countries and/or applicable across multiple types of health campaigns such as immunization, NTDs, malaria, or nutrition).

We are especially interested in novel approaches that draw on innovation from large-scale delivery models outside of the health sector, which may include interventions used in the private sector.

Funding Details: See Rules and Guidelines.

Additional Details

Internal HRS Deadline: October 30, 2019
Sponsor Deadline: November 13, 2019

Canadian Hemophilia Society: Research Programs

Dream of a Cure: Supporting research towards improving the health and the quality of life of all people with inherited bleeding disorders and finding a cure have been goals of the Canadian Hemophilia Society (CHS) since it was founded in 1953. Since 1990 through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, at finding a cure.

Funding Details: $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. In addition, support will be available for Canadian medical or science students for up to 4 months, for a maximum stipend of $6,000 each, who are interested to work on research projects related to inherited bleeding disorders.

Care until Cure: The CHS / Pfizer Care Until Cure Research Program was established in the year 2000 in collaboration with Wyeth Canada, now Pfizer. Pfizer Canada strives every day to help Canadians live healthy, balanced lives. They do that by discovering and developing innovative medicines. As a company, they’re dedicated to building healthier communities and empowering Canadians to make healthier choices every day. At Pfizer Canada, they believe that to be truly healthy, it takes more than medication.

This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder.

For the 2020-2021 granting period of the program, specific areas of interest have been identified and investigators are encouraged to submit proposals within these areas.

Funding Details: For the CHS / Pfizer Care Until Cure Research Program, individual grants valued at $75,000 per year will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. Grant funding will begin on April 1, 2020.

Novo Nordisk Canada Psychosocial: Created to engage professionals/graduate students from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.

The Research Grants are made possible thanks to generous financial support from Novo Nordisk Canada. Novo Nordisk develops, manufactures and markets products that make a significant difference to patients, the medical profession and society. Novo Nordisk has a leading position within areas such as coagulation disorders, growth disorders and hormone replacement therapy. In addition, Novo Nordisk is also the world leader in diabetes care. The CHS is proud to be in a partnership with Novo Nordisk in order to offer this important Research Program.
**Funding Details:** The primary intent of this program is to offer one or two $20,000 research grants, to a maximum of $40,000 for one year.

**Additional Details**

**Internal HRS Deadline:** November 1, 2019  
**Sponsor Deadline:** November 15, 2019

**Fulbright Canada - Foundation for Educational Exchange Between Canada and the United States of America: Programs for Canadian Scholars**

**Traditional Fulbright Scholar Award:** Traditional Fulbright awards are open to Canadian scholars in all fields and are designed to enable emerging and established scholars, post-doctoral researchers and experienced professionals to conduct research, teach, or undertake a combination of both activities for one semester or a full academic year at any university or research center of their choice in the United States.

Specialization: While the competition is open to all disciplines, Fulbright Canada is particularly interested in encouraging research on contemporary issues relevant to Canada, the United States and the relationship between the two countries. Applicants should also clearly document the need to be in residence in Canada to carry out the project.

**Funding Details:** $12,500 USD for 1 semester (4 months) beginning in either September 2020 or January 2021.

**Research Chairs Program:** Fulbright Canada Research Chairs are intended for Canadian citizens who are exceptional scholars and/or experienced professionals who wish to conduct research and/or lecture in the United States.

Fulbright Canada Research Chairs are pre-arranged affiliations that allow scholars to conduct research/lecture on subjects important to that university. Partner universities are excited to welcome the Fulbright Visiting Chairs into campus life and encourage them to engage with students, faculty, and the broader community. Fulbright Visiting Research Chairs can guest lecture in university courses, mentor students, lecture in public venues, network, and promote their research, while representing the Fulbright program, and their home and host institutions.

**Funding Details:** $25,000 to $50,000 USD from 4 to 9 months beginning in either September 2020 or January 2021.

**Additional Details**

**Internal HRS Deadline:** November 1, 2019  
**Sponsor Deadline:** November 15, 2019

**Canadian Blood Services: BloodTechNet Award Program**

Through the BloodTechNet award, Canadian Blood Services supports the development of innovative educational projects that network the Transfusion, Cellular Therapy and Transplantation communities in Canada. These projects deliver educational tools and resources that support the development of skills, knowledge and expertise of the health professionals in this network.

**Funding Details:** The total budget available for the 2019 BloodTechNet Award Program competition is $50,000. The BloodTechNet Award Program competition will support projects with a proposed budget of up to $50,000. The number of awards funded will depend on the requested budgets and the recommendations of the review committee.

**Additional Details**

**Internal HRS Deadline:** November 15, 2019  
**Sponsor Deadline:** November 29, 2019

**Canadian Blood Services: Graduate Fellowship Program**

Canadian Blood Services Graduate Fellowship Program provides stipend support for young investigators who want to initiate or continue training in the field of transfusion science. Graduate students undertaking full-time research training in a Canadian institution are invited to apply. The fellowship has a value of $25,000 per annum with an additional travel allowance of $1,000 per year of support. Students may be supported for a maximum of four years, with a requirement for successful renewal half way through the fellowship.

**Funding Details:** The maximum value of each Fellowship is $25,000 per annum, with an additional travel allowance of $1,000 per year of support. Students may be supported for a maximum of four years, with a requirement for renewal at year two.

**Additional Details**

**Internal HRS Deadline:** November 15, 2019
**Canadian Blood Services: James Kreppner Award Program**
The James Kreppner Award program supports legal and/or bioethical research relevant to Canadian Blood Services. Research priorities for the James Kreppner Award include the legal and/or bioethical aspects of (a) donation, collection, storage, and use of blood, blood products, and novel uses of hematopoietic stem cells; and (b) organ and tissue donation and transplantation.

**Funding Details:** One project with up to $50,000 for a period of one year.

**Additional Details**
**Internal HRS Deadline:** November 15, 2019  
**Sponsor Deadline:** November 29, 2019

---

**The Klarman Family Foundation: Eating Disorders Research Grants Program**
The fundamental aim of this grants program is to understand the biology underlying the psychiatric disease anorexia nervosa, with the goal of accelerating progress toward prevention and treatment. We fund grants to academic researchers for 1 – 3 year projects to research the biology of this disease, and the questions of how and why it develops and persists. We encourage approaches that incorporate neurobiology with an up-to-date understanding of the symptoms and dysfunction associated with anorexia nervosa.

**Funding Details:** Up to $750,000 over 1 - 3 years.

**Additional Details**
**Internal HRS Deadline:** November 25, 2019  
**Sponsor Deadline:** December 9, 2019

---

**The Michael J. Fox Foundation: Edmond J. Safra Fellowship in Movement Disorders**
Movement disorder specialists (neurologists with subspecialty training in Parkinson's disease and other movement disorders) serve as an important bridge between scientific advances in the lab and positive patient outcomes in the care setting. While the demand for movement disorder specialists is increasing, not enough neurologists are receiving this vital training. To address this unmet need, The Michael J. Fox Foundation (MJFF), in collaboration with longtime partner the Edmond J. Safra Foundation, introduced The Edmond J. Safra Fellowship in Movement Disorders. By funding academic centers to train new movement disorder clinician-researchers, this program aims to develop a network of highly trained specialists to be the next generation of leaders in Parkinson’s research and clinical care.

The program grants funding directly to academic centers, which then must identify and train a new movement disorder fellow over a two-year period. Grant support cannot be used for a fellow already enrolled or selected. The Edmond J. Safra Fellowship in Movement Disorders is open to academic centers worldwide; previously awarded centers qualify to apply.

**Funding Details:** $90,000 per year.

**Additional Details**
**Internal HRS Deadline:** November 29, 2019  
**Sponsor Deadline:** December 13, 2019

---

**Alex’s Lemonade Stand: Epidemiology Grants**
Epidemiology awards will support investigators pursuing research studies in human populations using epidemiological approaches, in order to significantly contribute to the understanding of childhood cancers.

This grant mechanism is designed to support hypothesis-driven research that focuses on the epidemiology, early detection and prevention of childhood cancer or comparative effectiveness and outcomes research related to detection, prevention, and treatment.

**Funding Details:** $100,000 per year for two years for direct costs.

**Additional Details**
**Internal HRS Deadline:** December 2, 2020  
**Sponsor Deadline:** December 16, 2020

---

**Alex’s Lemonade Stand: Young Investigator Grants**
The Young Investigator grant is a 3-year award designed to support scientists in the early stages of their research careers, such as postdoctoral or clinical fellows. Outstanding mentorship and demonstration of a career plan that shows commitment to pediatric cancer investigation are critical components of a successful application.

**Funding Details:** Up to $150,000 over three years. A maximum of $50,000 in total costs will be awarded to applicants annually.

**Additional Details**
- **Internal HRS Deadline:** December 2, 2020
- **Sponsor Deadline:** December 16, 2020

### Alex’s Lemonade Stand: Crazy 8 Initiative
The Crazy 8 Initiative Award will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today. This award is designed to coalesce cross-disciplinary cores of scientists working collaboratively in order to accelerate the pace of new cure discovery. The proposal should address a topic that is responsive to at least one of the four pediatric cancer research themes listed above. It is expected that successful applications will address one or more of the eight disciplines that formed the basis of the Crazy 8 initiative.

Investigations may involve the exploration of a novel scientific hypothesis or the development of new model systems, tools or technologies that have the potential for significant impact on the field of childhood cancer. Collaboration and data sharing are a priority for this research program. We expect successful applications to propose multidisciplinary teams with a very clear plan for collaboration that would empower the study of big ideas that would not be easily addressable otherwise. Childhood cancer research applicants are encouraged to bring new, necessary expertise into the field. The awards will be judged on scientific soundness, significance and the potential for impact on improving the lives of children with cancer.

**Funding Details:** The requested budget should be in proportion to the scope of the proposed project and its corresponding potential for impact. Depending on the type of project and the size of the team, the requested budget should be in the range of $1-5 million USD over 4 years. Cost efficiency will be one of the major considerations in review and funding decisions. ALSF will pay up to 10% in indirect costs; if the applicant elects to request indirect costs, the budget may not exceed the range of $1-5 million USD. Funding is contingent upon satisfactory progress as determined by a Crazy 8 Initiative Scientific Advisory Board.

**Additional Details**
- **LOI Deadline:** October 1, 2019
- **Internal HRS Deadline:** January 6, 2020
- **Sponsor Deadline:** January 20, 2020

### Leukemia & Lymphoma Society: Specialized Centre of Research Program
LLS’s Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

**Funding Details:** The maximal annual total cost is $1,000,000 for each year of the five year grant. The maximum annual direct cost is $833,333.33 while the maximum annual indirect cost is $166,666.66. The SCOR Director has the authority to budget these funds among the various Projects and Cores.

**Additional Details**
- **LOI Deadline:** October 1, 2019
- **Internal HRS Deadline:** February 28, 2020
- **Sponsor Deadline:** March 15, 2020

### Alex’s Lemonade Stand: Innovation Grants
Innovation Grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. Proposals should have clinical translation in view. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator’s prior research but for which a strong case is made for the potential impact on childhood cancers.

**Funding Details:** Up to $125,000 per year for two years for direct costs only.

**Additional Details**
- **LOI Deadline:** November 4, 2019
Society of Facioscapulohumeral Muscular Dystrophy: Research Grant
The FSH Society offers grants, research fellowships and postdoctoral fellowships to support research relevant to understanding the molecular genetics and cause of Facioscapulohumeral Muscular Dystrophy (FSHD).

The general areas of interest include tissue, cell and molecular biology studies of FSHD, the development of animal models for FSHD, biomarkers and outcome measurements, and clinical trial readiness.

Proposals are sought for research that helps with understanding of the genetic, pathophysiological, neuromuscular and developmental mechanisms of the disease. There is also interest in the development of cell, small-molecule and gene therapy, genomic engineering technologies and other therapeutic programs that may arise from that understanding.

Please submit a single-page introductory cover letter plus a one- or two-page descriptive summary of the proposed research—enough for a decision from the Scientific Advisory Board. The letter of intent may be submitted at any time to the FSH Society, Attention: Dr. David Housman, Scientific Advisory Board Chairman, FSH Society, 450 Bedford Street, Lexington MA 02420. Email the letter to daniel.perez@fshsociety.org.

Funding Details: $7,500 - $125,000 for 1 year (an average award is approximately $57,500).

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis February 28/29 and August 31 annually.

National Multiple Sclerosis Society: Pilot Research Grants
The Society funds high-risk pilot grants to quickly test novel ideas. Funding is provided for one year to test innovative, cutting-edge ideas or untested methods, and to gather sufficient preliminary data to apply for longer-term funding. We welcome applications for studies related to multiple sclerosis that may serve to advance our mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation.

Funding Details: See additional details.

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis May 8, 2019 (pre-application is due May 6), September 11, 2019 (pre-application is due September 9), January 8, 2020 (pre-application is due January 6).

Alex's Lemonade Stand: RUNX1 Early Career Investigator Grant
The key objective is to promote the establishment of a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder. We believe that providing capital to early career investigators not only injects funding to where it is needed most, but also cultivates a new cohort of investigators who will be invested in an area of research that historically has had limited attention.

The RUNX1 Early Career Investigator grant is a 3-year award designed to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with RUNX1-FPD. Collaboration and data sharing are a priority for this research program. The RUNX1 Research Program and ALSF host an annual scientific meeting that brings together grant recipients and other scientists. Grant recipients are expected to present their progress as part of the annual review.

Funding Details: $180,000 over 3 years (maximum $60,000 per year may be requested).

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis June 27, September 26 and December 26 annually.

Canadian Cancer Society: Travel Awards
A limited number of Travel Awards to PhD or MD/PhD students, and post-doctoral/medical/clinical fellows are available. The purpose of this program is to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting.

Funding Details: It is anticipated that up to 10 Travel Awards will be awarded in each competition (30 awards per year).

Note: Eligible expenses include: 1) Conference registration fees; 2) Accommodations; and 3) Transportation, and will not exceed $2,000.
**Canadian Cancer Society: Junior Investigator Grant Panel Travel Award**

Application guides can be found on the [EGrAMS documentation for applicants](#) page.

The Canadian Cancer Society is pleased to offer a special initiative to allow junior investigators in cancer research to gain knowledge and understanding of the Canadian Cancer Society peer-review process. During the year, through different funding opportunities, applications spanning all disciplines of cancer research are evaluated and ranked for funding.

Selected investigators from across Canada will be provided funds to reimburse travel costs to Toronto to observe a grant panel meeting. This unique opportunity will provide junior faculty members with an “inside look” at how research grants are reviewed in order to help structure their own grant proposals in future.

Eligible applicants are investigators in cancer research at the end of their Post-doctoral fellowship or within the first few years of their academic appointment. Priority will be given to those who have yet to be awarded a grant from a Canadian granting agency. Applications for these limited funds will be accepted via [EGrAMS](#) and require Department or Institution Head sign-off prior to submission.

Please view the list of [current grant panels](#) for more information on available panels.

**SickKids Foundation: Community Conference Grants**

The objective is to bring together families with researchers and clinicians for medical presentations, workshops, symposia and family-oriented discussions. The conference helps to ensure families receive access to the most up-to-date information regarding their children’s health. The grant will support events which are organized by and/or for families with children with health challenges, including, but not limited to children with acute illness, chronic illness and disabilities.

**Funding Details:** Awards are limited to an annual maximum request of $5,000. The Foundation will fund a maximum of three consecutive annual events organized by any single organization.

**Cancer Research Society: Translational Research Partnership Program**

The Translational Research Partnership Program supports collaborative projects in cancer research to help accelerate the development of new treatments and/or technologies for the benefit of patients. Our Translational Research Partnership strategy is bold and ambitious. We aim to break down the boundaries between research disciplines, which may include researchers from non-cancer backgrounds, in order to find innovative solutions to prevent, detect and treat cancer. We partner with a range of organizations to maximize the impact of research on patient outcomes.

Projects must meet the following conditions:

- Be translational research and may include clinical trial studies
- Basic research projects are out of scope
- Aim the development of a therapeutic and/or novel technologies
- Have excellent preliminary data to support the proposed project

The research team must consist of at least one principal investigator and one co-investigator. The inclusion of a variety of non-cancer disciplines is encouraged to drive the development of novel technologies and to take thinking from other fields that have not yet been applied to cancer.

All projects are evaluated based on the following criteria:

- Scientific excellence and innovativeness of proposed project
- Expertise of the multidisciplinary team
- Quality of preliminary data and feasibility
- Financial partner’s engagement
- Anticipated benefits for cancer patients
**Funding Details:** A maximum of $1,500,000 over up to 3 years per project of which up to 50% may come from the Cancer Research Society.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

---

**HHS: Clinical Health Professional Travel Awards**

The Clinical Health Professionals Research Travel Award provides support for eligible non-physician Health Professionals to present their work at a scientific meeting of relevance to their practice/research.

**Funding Details:** Up to six awards on a competitive basis will be given within a calendar year, and are each valued up to a maximum of $2,500 for a national conference or $3,500 for international (funds in Canadian dollars).

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

This funding program is led by Dr. Sandra Carroll, Director, Clinical Health Professional Research, carroll@mcmaster.ca. Interested candidates are recommended to contact Dr. Carroll or Daniela Bianco biancdan@hhsc.ca in advance of their submission. Please send inquiries to Donna Catherwood, catherwood@hhsc.ca.

---

**The Ontario HIV Treatment Network (OHTN), Endgame Funding Program: Community-Based Research and Evaluation (CBR&E) Awards**

The OHTN Community-Based Research & Evaluation Fund (CBR & E Fund) is designed to help achieve the mission of the OHTN; to improve the health and well-being of people living with and at risk of HIV in Ontario, through a network that promotes research and evidence to drive change. The CBR & E Fund will assist communities by supporting both the production and discovery of knowledge through community-based research, and the use of evidence to drive programming through participatory program evaluation.

OHTN is committed to funding scientifically rigorous, community relevant research that will have a short-to medium-term impact on those most affected by HIV in Ontario:

- People living with HIV/AIDS
- Gay men and other men who have sex with men, including gay, bi, and queer trans men, youth and newcomers
- African, Caribbean and Black men and women, including youth
- Aboriginal men and women, including youth
- Men and women who use drugs
- Women, including trans women, who are at risk (e.g. have unprotected sex or share drug equipment with people from the populations listed above)

The CBR & E fund will provide grant support to eligible community-initiated HIV research and evaluation projects that explore questions of importance to community-based organizations, and have the potential to have a meaningful impact on those most affected by HIV in Ontario in the next 2-5 years.

**Funding Details:** $25,000 to $50,000 for 1 year.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis March 1, June 7, September 6 and December 6, 2019.

---

**Ontario Brain Institute (OBI): Event Funding Program**

The Ontario Brain Institute (OBI) is committed to working together with brain health-related organizations in order to increase the capacity of their work in Ontario. The program especially looks to support events that embody OBI’s principles of integration and collaboration.

**Funding Details:** Up to $5,000.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis in January, May and September.

---

**Crohn’s & Colitis Foundation: IBD Ventures**

Is your organization engaged in the discovery or development of a novel product with the potential to help patients with inflammatory bowel diseases? If so, we want to hear from you!

The Crohn's & Colitis Foundation seeks to accelerate the development of products that aim to improve the quality of life of patients...
with inflammatory bowel diseases. Toward that end, the Foundation has launched IBD Ventures, a new program and dedicated funding mechanism to support product-oriented research and development. Companies and academic investigators can apply.

**Funding Details:** Up to $500,000 per project per year will be considered. In addition, funded programs will be offered accelerator resources and advising.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

### Ontario Genomics: Genomic Applications Partnership Program (GAPP)

The Genomic Applications Partnership Program (GAPP) funds downstream research and development (R&D) projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities. These organizations should be committed to commercializing or implementing the outcomes of the project.

Projects are led by the Receptor organization (Canadian or international) but are active collaborations with a Canadian academic researcher. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada.

The GAPP aims to:

- Accelerate the application of Canadian genomics-derived solutions from academia to real-world opportunities and challenges defined by industry, not-for-profit and public-sector Receptors.
- Channel Canada’s genomics capacity into sustainable innovations that benefit Canadians.
- Enhance the value of Canadian genomics technologies by de-risking and incentivizing follow-on investment from industry and other partners.
- Foster mutually beneficial collaboration and knowledge exchange between Canadian academia and technology receptors.

**Funding Details:** 1/3 investment from Genome Canada, 1/3 provided by the Receptor partner (cash and/or in-kind) and 1/3 of other co-funding (non-Genome Canada). For more information see Section 9 and Appendix 2 of the GAPP Investment Strategy and Guidelines.

**Additional Details**

**LOI Deadline:** Accepted on a rolling basis February 19, May 21, August 15.

### Weston Brain Institute Postdoctoral Scholars at Oxford

The Weston Brain Institute Postdoctoral Scholars at Oxford program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford.

**Funding Details:** £57,000 per year (£44,000 per year + benefits) for 2 years.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis, until 2 positions at a time are filled.

### Weston Brain Institute International Fellowships: Canada

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Weston Brain Institute is pleased to launch our International Fellowships: Canada program. The program will support top Canadian PhD students to travel to and work in world-renowned international labs for up to 12 months, to further their translational research on neurodegenerative diseases of aging.

**Funding Details:** $60,000 per year, prorated at $5,000 per month to fit shorter travel and specific project needs.

**Additional Details**

**Sponsor Deadline:** Applications are being accepted on a rolling basis.

### Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline

Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. [More information here](#).
Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer’s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology.

Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

Funding Details: $50,000 to $100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

Additional Details
LOI Deadline: Accepted on a rolling basis January 18, April 12, July 12, October 11.
Sponsor Deadline: Accepted on a rolling basis February 8, May 10, August 9, November 8.

Alzheimer’s Drug Discovery Foundation: Drug Discovery Program

The Alzheimer’s Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer’s disease, related dementias, and cognitive aging by supporting promising therapeutic approaches.

The Drug Discovery RFP supports:

- Novel drug programs aiming to advance novel lead molecules to the clinical candidate selection stage. This includes small molecules and biologics (e.g., antibodies, peptides, gene therapies).
- Repurposed/repositioned programs aiming to build preclinical evidence in relevant animal models for repurposed drugs (existing drugs that are approved for other diseases and conditions) and repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved).

Funding Details: $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

Additional Details
LOI Deadline: Accepted on a rolling basis January 18, April 12, July 12, October 11.
Sponsor Deadline: Accepted on a rolling basis February 8, May 10, August 9, November 8.

Alzheimer’s Drug Discovery Foundation: Neuroimaging & CSF Biomarker Development Program

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology.

This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to:

- Clearly demonstrate target engagement for novel therapeutics
  The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.
- Detect signs of disease earlier and monitor progression
  We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer’s disease. We also seek prognostic markers that can predict rates of cognitive decline.
- More accurately diagnose and distinguish between dementia subtypes
  Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.
Funding Details: $150,000-$600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

Additional Details
LOI Deadline: Accepted on a rolling basis January 18, April 12, July 12, October 11.
Sponsor Deadline: Accepted on a rolling basis February 8, May 10, August 9, November 8.

McMaster University, McMaster Institute for Research on Aging (MIRA), Canadian Longitudinal Study on Aging (CLSA): Call for Proposals
The CLSA is a large, national, long-term study of more than 50,000 men and women who were between the ages of 45 and 85 when recruited. These participants will be followed until 2033, or death. The aim of the CLSA is to find ways to help us live long and live well, and understand why some people age in healthy fashion while others do not.

Researchers must notify Laura Harrington, Managing Director, MIRA, of their intent to apply for CLSA data access to be considered for MIRA funding. MIRA funds are allocated only to projects that do not have any other funding for this purpose.

MIRA membership is required to be eligible.

Data access applications are accepted three times per year.

Funding Details: MIRA can support access fees of $3,000 for a maximum 10 applications.

Sponsor Deadline: Ongoing
Please contact Audrey Patocs at patocsae@mcmaster.ca with intent to apply or any inquiries. Applications will be handled through the MIRA office.

McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities
The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

Funding Details: Maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year.

Additional Details
Sponsor Deadline: Ongoing
Please contact Audrey Patocs at patocsae@mcmaster.ca with intent to apply or any inquiries. Applications will be handled through the MIRA office.

MITACS Globalink Research Award
The Mitacs Globalink Research Award provides funding for senior undergraduate and graduate students, and postdoctoral fellows in Canada to conduct 12–24-week research projects at universities overseas. The following opportunities support travel and research from Canada to universities in:
Australia, Brazil, China, EU member countries: In France, both universities and Inria Research Centres are eligible host institutions, Israel, India, Japan, Korea, Mexico, Norway, Saudi Arabia, Tunisia, United Kingdom, United States.

Funding Details: $6,000 to conduct 12-24-week research projects at universities overseas.

Additional Details
Sponsor Deadline: Ongoing

MITACS Accelerate Fellowship
The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills. Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

Funding Details:
- **Master’s students** - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
- **PhD students** - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**Weston Brain Institute: Big Ideas**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.

Based on success of previous programs, the Institute is expanding our support to new formats while maintaining the same mandate of accelerating the developments of therapeutics for neurodegenerative diseases of aging through translational research.

The Institute is considering supporting a large-scale, pivotal project to significantly advance research in our field. With this call, we are seeking to identify highly impactful ideas for consideration. Of particular interest are ideas that will establish Canada as the world leader in a particular area.

**Goal:** To support a large-scale, pivotal project that will significantly and sustainably advance research in the field of translational research on neurodegenerative diseases of aging.

**Funding Details:** From $5,000,000 to $20,000,000.

**Additional Details**
**Sponsor Deadline:** Ongoing

---

**Weston Brain Institute: Early Phase Clinical Trials: Canada**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above and can be working outside Canada.

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

**Additional Details**
**Sponsor Deadline:** Ongoing

---

**OCE Voucher for Innovation and Productivity II (VIP II) Program**
The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-secondary institutions' skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

**Funding Details:** The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000.

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**MITACS Accelerate Program**
Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

**Funding Details:** Funding starts at $15,000

**Additional Details**

**Sponsor Deadline:** Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

## Department of Defense (DoD) Combat Readiness-Medical Research Program (CRRP): Rapid Development and Translational Research Award

The CRRP seeks to enhance medical capabilities at the point of greatest need in order to save the most lives in future combat scenarios, which may be complicated by limited resources, austere conditions, and/or mass casualty events. The intent of the FY19 CRRP RDTRA is to support research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines. Applicants may leverage existing resources in translational research to address high-impact research ideas or unmet needs in delivering lifesaving care to the Warfighter during prolonged and en route care in austere and combat environments. Research of interest may include knowledge products, “knowledge resulting from research with the potential to improve individual or public health,”2 and solutions that can accelerate the introduction of military-relevant health products or technologies into clinical and/or operational use. For this award mechanism, the definition of “leveraging” is as follows: An investigator basing a research project on existing resources in order to amplify potential gains in knowledge or accelerate technical maturity. Projects should consider the varied expertise levels of the medical providers and the possible diverse environmental conditions in combat situations. Proposal/application submissions are encouraged to include characteristics relevant to military use in non-hospital settings in theater, but submissions that propose solutions to advance civilian trauma care are not precluded, since civilian trauma care frequently informs and influences trauma care in the military, and vice versa.

Preclinical research, including animal studies, that is already supported by substantial preliminary or published data and strongly validates clinical translation is appropriate for this award mechanism.

Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 CRRP RDTRA will not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** October 23, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** October 30, 2019

**Sponsor Deadline:** November 13, 2019